ERS Express Startup License
At ERS Genomics, we understand the importance of efficient access to cutting-edge technology. Our Express License Application is designed to provide an affordable and quick solution for non-exclusive internal research use of CRISPR/Cas9.
to get access to the world's largest patent portfolio for CRISPR/Cas9.
Eligibility Criteria
To qualify for our Express License, your company must meet the following criteria:
Size
Your company must have fewer than 15 employees.
Funding
Your company must have less than $10,000,000 in funding.
Use
Your company must be actively or seek to be using CRISPR technology for internal research purposes.
Commercialization
Your company must not be currently commercializing or intent to commercialise CRISPR technology under this license.
Why CRISPR/Cas9?
CRISPR/Cas9 technology has revolutionized the field of genetic research, offering unprecedented precision and flexibility. For internal research, CRISPR/Cas9 can be used to:
Gene Editing
Beyond simple modifications, CRISPR/Cas9 enables precise insertions, deletions, and targeted gene disruptions. Researchers can insert entire gene sequences for synthetic biology applications, engineer new traits, and design complex biological systems, expanding possibilities in areas like metabolic engineering, biofuel production, and the development of novel biomaterials.
Disease Modeling
By creating accurate disease models in cell lines and animal systems, CRISPR/Cas9 allows researchers to probe the underlying mechanisms of diseases and validate potential therapeutic targets, advancing drug discovery and development.
High-Throughput Screening
CRISPR/Cas9 supports genome-wide screens to identify genes crucial to specific biological pathways & responses as well as for drug target identification and validation.
Functional Genomics
CRISPR/Cas9 empowers researchers to investigate gene function and regulation comprehensively, revealing how specific genes contribute to complex traits and diseases. This insight lays the foundation for targeted therapies, personalized medicine, and a deeper understanding of genetic contributions to health and disease.
Our Express License Application process is designed to be fast, simple, and accessible, particularly for startups and small companies. We recognize the unique challenges these organizations face and aim to remove barriers to accessing this transformative technology.
Why Choose Our Express License?
Speed
Our streamlined process ensures that you can obtain a license quickly, allowing you to focus on your research without unnecessary delays.
Simplicity
The application process is straightforward and user-friendly, minimizing administrative burdens.
Accessibility
Our affordable licensing model is tailored to meet the needs of startups and small companies, ensuring that innovative research can thrive regardless of your organization's size or funding level.
Apply Now
Take the first step towards accessing the most comprehensive CRISPR/Cas9 patent portfolio available. Our express licensing process is designed to get you up and running quickly, so you can leverage the power of CRISPR/Cas9 for your research needs.
Thank you for choosing ERS Genomics for your CRISPR/Cas9 licensing needs. We look forward to supporting your innovative research endeavors.